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Abstract
Background: Poor response to ovarian stimulation with exogenous gonadotrophins occurs in 9–24% of women
undergoing in vitro fertilisation (IVF) treatment, which represents an estimated 4000–10,000 women per year in the UK.
Poor responders often have their treatment cycle cancelled because of expected poor outcome.
One treatment strategy that may influence outcome is the choice of pituitary suppression regimen prior to the initiation
of ovarian stimulation. The three commonly used pituitary suppression regimens in IVF treatment are:
(1) the GnRH agonist long regimen,
(2) the GnRH agonist short regimen and
(3) the GnRH antagonist regimen.
A systematic review of randomised controlled trials of these pituitary suppression regimens has shown the evidence to
be either inconclusive or inconsistent. We therefore designed a three arm randomised trial to evaluate the effectiveness
of these regimens in women who had poor ovarian response in a previous IVF treatment cycle.
Methods/design: Consenting, eligible women will be randomised to one of the three regimens using an internet-based
trial management programme that ensures allocation concealment and employs block randomisation and minimisation
for prognostic variables. The primary outcome is the number of oocytes retrieved. Other outcomes include total dose
of follicle stimulating hormone (FSH) used for ovarian stimulation, mature oocytes retrieved, embryos available for
transfer, implantation rate and clinical pregnancy rate.
The sample size for this trial has been estimated as 102 participants with 34 participants in each of the three arms.
Appropriate interim analysis will be conducted by a Data Monitoring and Ethics Committee (DMEC), and the final analysis
will be by intention to treat.
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Background
Poor ovarian response, defined as failure of the develop-
ment of sufficient number of mature follicles to proceed
to oocyte retrieval or yielding only a few oocytes following
gonadotrophin stimulation in women undergoing in
vitro fertilisation (IVF) treatment, occurs in 9–24% of
women [1]. Poor ovarian response is likely to be an
increasing problem with women delaying childbearing
and presenting for treatment later in their reproductive
life. In comparison to normal responders these patients
have impaired fertilisation rates, lower embryo quality
and decreased pregnancy rates [2]. Poor responders often
have their treatment cycle cancelled because of expected
poor outcome [3]. This causes emotional distress for the
couple, as well as a financial burden on the couple or the
service provider.
Treatment of poor responders who are undergoing IVF
treatment remains a challenge. Various treatment regi-
mens and interventions have been proposed in an effort
to improve ovarian response and IVF outcome in this
group of patients. These include different regimens for
pituitary suppression, controlled ovarian hyperstimula-
tion (COH) as well as adjuvant therapies [4]. Currently,
the choice of pituitary suppression regimens proposed for
the management of poor responders is mainly based on
individual centre's or clinician's preferences, with no sin-
gle protocol considered to be superior over the other. Of
the various available pituitary suppression regimens, the
three commonly used ones are:
(1) the GnRH agonist long regimen,
(2) the GnRH agonist short regimen and
(3) the GnRH antagonist regimen.
To address the question of their effectiveness, we per-
formed a systematic review and meta-analysis. Literature
searches were conducted in MEDLINE, EMBASE, the
Cochrane Database, National Research Register and ISI
proceedings to identify randomised trials comparing the
effects of the above three regimens. We identified seven
randomised controlled trials comparing the regimens
with each other.[5-11] There were no trials that compared
all three regimens against each other. The quality of these
7 randomised trials was generally poor (only 2/7 trials
had adequate allocation concealment reported). These tri-
als were also generally small, leading to imprecision in
their findings, even when combined in a meta-analysis
(Figure 1). Furthermore, there was substantial clinical and
statistical heterogeneity amongst the trials. The findings
were inconclusive or inconsistent (Figure 1). A well
designed, adequately powered, three arm trial comparing
the long GnRH agonist regime versus the short GnRH ago-
nist regime versus the GnRH antagonist regime is there-
fore needed.
Methods/design
Objective
In the proposed trial we will evaluate which of the three
commonly used down regulation regimens is the most
Meta-analysis of the number of oocytes retrieved with different pituitary suppression regimens in poor responders Figure 1
Meta-analysis of the number of oocytes retrieved with different pituitary suppression regimens in poor responders.Reproductive Health 2007, 4:12 http://www.reproductive-health-journal.com/content/4/1/12
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effective for women who have shown poor response in
their previous IVF treatment cycle.
Design
A prospective, allocation concealed, assessor-blind, three-
arm randomised-controlled-trial.
Primary endpoints
￿ Number of eggs retrieved per IVF treatment cycle started.
Secondary endpoints
￿ The total dose of follicle stimulating hormone (FSH)
used for ovarian stimulation
￿ The number of mature eggs retrieved
￿ The number of embryos available for transfer
￿ The clinical pregnancy rate and
￿ The embryo implantation rate
Inclusion Criteria
Any woman undergoing an IVF treatment cycle who fits
the criteria to be a "poor responder" is eligible to partici-
pate in the trial.
For this study a "poor responder" is defined as a woman
who had a previous IVF treatment cycle in which she was
stimulated with a daily dose of FSH of 300 IU or more and
￿ Produced an inadequate number of mature follicles
(three or less follicles measuring > 17 mm) following
stimulation for at least nine days; OR
￿ Had three or less oocytes retrieved at oocyte retrieval.
Exclusion Criteria
￿ Women aged over 40 years.
￿ Women with a single ovary.
Randomisation
Third party, distant, internet-based block randomisation
with minimisation will be used to ensure randomisation
and complete allocation concealment. The aim of mini-
misation would be to balance for the following prognostic
variables (age, body mass index, previous pregnancies and
previous live birth). Women may be randomised into the
study by internet randomisation [12] or by telephoning a
central office.
Blinding
The trial will be a single-blinded study, where the asses-
sors (the doctor performing the egg collection procedure
and the embryologist involved in identifying and assess-
ing the eggs) are blinded to the treatment regimen.
Methods
All women who have had poor ovarian response in a pre-
vious IVF treatment cycle and who wish to undertake
another IVF treatment cycle are invited to participate in
the trial. The trial details are explained to the patient by a
doctor at their clinic appointment. An information sheet
[see Additional file 1] explaining the trial is given which
also has a contact number to telephone and speak to the
trial investigators. If the woman subsequently agrees to
participate in the trial she is requested to sign a consent
form [see Additional file 2]. The woman is then ran-
domised to one of the three trial regimens and informed
which regimen she has been randomised. Should the
woman need more time to decide the clinic doctor will
gain verbal permission for the investigators to call and
ascertain whether the patient wishes to enrol on the trial.
If the patient does wish to enrol then one of the investiga-
tors will make an appointment for the patient to sign the
consent form. If the woman declines to participate then
no further action is required with regard to the trial and
the woman will receive standard care. The flowchart in fig-
ure 2 describes the participant flow in the trial. Details of
all participants and outcomes are recorded on the case
report form [see Additional file 3].
The treatment regimens
GnRH agonist long regimen (Figure 3)
Pituitary down-regulation with GnRH agonist, nafarelin
(Synarel; Pharmacia, UK) starts on day 21 of the men-
strual cycle. Nafarelin nasal spray is taken at a dose of two
sniffs, twice a day, where one sniff equals 200 micro-
grams. The woman will generally have menstruation
within two weeks of starting nafarelin at which point she
attends the assisted conception unit (ACU) for a transvag-
inal ultrasound scan (TVS) to confirm down regulation
(quiescent ovaries with follicles < 10 mm diameter and
endometrium < 5 mm in thickness). On confirmation of
down regulation, ovarian stimulation is commenced with
FSH, follitropin alfa (Gonal-F; Serono, UK) at 450 IU
daily by subcutaneous injection. The dose of the nafarelin
nasal spray is halved (one sniff, twice a day) during ovar-
ian stimulation. The woman then attends for a TVS nine
days after starting ovarian stimulation and is instructed to
administer huaman chorionic gonadotrophin (HCG)
subcutaneously when criteria for egg collection are met
(see below). FSH and nafarelin are continued until HCG
administration.
The approximate duration of this treatment regimen (ie
from the start of nafarelin nasal spray, commenced on day
21 of the menstrual cycle, until the pregnancy test is per-
formed) is 6 weeks.Reproductive Health 2007, 4:12 http://www.reproductive-health-journal.com/content/4/1/12
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GnRH agonist short regimen (Figure 4)
Treatment for this protocol starts on day 2 or 3 of the
menstrual cycle after a TVS has confirmed the ovaries are
quiescent and the endometrium thin (<5 mm). The ova-
ries are generally quiescent and the endometrium thin at
the beginning of a menstrual cycle. On the 2nd or 3rd day
of the menstrual cycle the woman commences nafarelin
nasal spray (one sniff twice a day, where each sniff equals
200 micrograms). This is continued until administration
of the HCG injection (approximately 10 to 15 days from
the start of nafarelin nasal spray). On the 3rd or 4th day
of the menstrual
cycle the woman commences FSH (450 IU daily by subcu-
taneous injection). The woman attends for a TVS on day 9
of ovarian stimulation and is instructed to administer
HCG when criteria for egg collection are met (see below).
FSH and nafarelin are continued until the day of HCG
administration.
The approximate duration of this treatment regimen (ie
from the start of nafarelin nasal spray, commenced on day
2 or 3 of the menstrual cycle, until the pregnancy test is
performed) is 4 weeks.
GnRH antagonist regimen (Figure 5)
Treatment with this regimen starts on day 2 or 3 of the
menstrual cycle. The woman will attend the ACU for a TVS
and if the ovaries are quiescent and the endometrium thin
(<5 mm) she will commence ovarian stimulation with a
daily dose of 450 IU of FSH subcutaneously. Following
this a TVS is performed on day 6 of ovarian stimulation to
identify the leading follicle. Scans are continued until the
leading follicle has a diameter of 14 mm which is usually
between days 6 to day 8 of ovarian stimulation. When the
leading follicle has reached a diameter of 14 mm, GnRH
antagonist, cetrorelix (Cetrotide; Serono, UK) 0.25 mg
daily is administered subcutaneously. The next TVS is per-
formed on day 9 of ovarian stimulation, when the woman
Participant flow chart through the PRINT trial Figure 2
Participant flow chart through the PRINT trial.Reproductive Health 2007, 4:12 http://www.reproductive-health-journal.com/content/4/1/12
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is instructed to administer HCG if criteria are met (see
below). FSH and cetrorelix are continued until HCG
administration.
The approximate duration of this treatment regimen (ie
from the start of FSH injections, commenced on day 2 or
3 of the menstrual cycle, until the pregnancy test is per-
formed) is 4 weeks.
The following steps of the treatment are the same for all
the three treatment regimens.
Criteria for HCG administration
When ≥ 3 follicles attain a mean diameter of ≥ 17 mm,
HCG, choriogonadotrophin alfa injection (Ovitrelle;
Serono, UK) 6,500 IU is administered subcutaneously.
Egg collection (oocyte retrieval)
Egg collection is performed 34–38 hours after the HCG
injection. Egg collection is routinely done under heavy
sedation.
Embryo transfer (replacement of embryos)
Embryo Transfer is performed two, three or five days fol-
lowing the day of egg collection, based on the number
and quality of embryos available.
Luteal support
All women undergoing IVF treatment are advised to self
administer progesterone pessaries (Cyclogest; Alpharma,
UK) 400 mg daily starting on the day of egg collection
until the day of the pregnancy test, then until 8 weeks of
pregnancy if the treatment is successful.
Pregnancy test
All women are requested to do a home urinary pregnancy
test 14 days from the day of egg collection.
Early pregnancy scans
All women having IVF treatment have two early preg-
nancy scans at 6 and 8 weeks gestation.
GnRH agonist long regimen Figure 3
GnRH agonist long regimen.Reproductive Health 2007, 4:12 http://www.reproductive-health-journal.com/content/4/1/12
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Trial statistics
Number of participants
Sample size calculation was based on the observed differ-
ences in eggs collected from existing literature as well as
on the judgement on what constitutes as a clinically Min-
imally Important Difference (MID), which was judged to
be increasing the number of oocytes retrieved from 3 to 5.
For this difference of 2 oocytes retrieved, with a standard
deviation of 2.5 (as observed in the existing literature), for
a power of 90% and an alpha of 5%, 102 women in total
will need to be recruited (34 each of the three arms of the
trial).
Statistical analysis
The analysis will be by intention to treat, and will be car-
ried out in the following four steps:
Step 1: Summarising trial data
Baseline data and outcome data will be summarised sep-
arately. For continuous variables (eg age and FSH level),
we will examine the distribution of the observations, and
if normally distributed we will then summarise them as
means with standard deviations (SDs). If they are non-
normally distributed, then medians and inter-quartile
ranges (IRQs) will be reported. For dichotomous data (eg
clinical pregnancy), we will provide proportions (or per-
centages).
For our main outcome measure (the number of oocytes
collected), as the number of oocytes is not a dichotomous
or continuous variable but is a count, and as it is more
likely not to be normally distributed, a model for count
such as the negative binomial model will be used for anal-
ysis.
In addition to the baseline and outcome data, we will also
summarise the recruitment numbers, those participants
lost to follow-up, protocol violations and other relevant
data.
Step 2: Inter-group comparisons
A test for overall comparison (eg ANOVA, or if assump-
tion for ANOVA are not met, a non-parametric equiva-
lence such as Kruskal-Wallis) will be employed for each
GnRH agonist short regimen Figure 4
GnRH agonist short regimen.Reproductive Health 2007, 4:12 http://www.reproductive-health-journal.com/content/4/1/12
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outcome across all three interventions (A, B, and C), and
if this is found to be significant (at a p-value of ≤ 0.05),
then we will proceed to pair-wise comparisons (i.e., A vs
B, B vs C, A vs C). We appreciate that multitudes of pair-
wise comparisons can suffer from Type I (false-positive)
error, and will therefore adjust for multiplicity of compar-
isons (by using steps such as Bonferroni and Tukey's pro-
cedure).
The statistical procedures for pair-wise comparisons will
depend on the nature of the data: for example, for dichot-
omous outcomes, we will use Fishers Exact Test or chi-
square as appropriate, and for continuous outcomes we
will use t-test if the observations in each trial arm are nor-
mally distributed; if non-normally distributed, then
Mann-Whitney-U test will be employed. Although p-val-
ues will be reported, the focus will be on providing 95%
confidence intervals around point estimates as these are
more useful in interpreting the findings of the trial.
Step 3: Sub-group analysis
We will give emphasis to planned (a priori) sub-groups in
our analyses. However, we are aware sub-groups analysis
can suffer from false positive (due to multiplicity of com-
parisons) and false negative (due to reduced sample sizes)
results, and will place limited importance in subgroup
findings in relation to the overall (global) findings. We
will use post-hoc subgroup analysis only for the purpose
of hypothesis generation.
Step 4: Adjustments and sensitivity analyses
If randomisation fails to achieve balanced groups, then we
will perform secondary analyses in which we will adjust
for unbalanced prognostic factors using procedures such
as logistic regression. If the primary unadjusted analysis
and secondary adjusted analysis are at discordance, then
we will give greater weighting to the primary analysis in
the interpretation of trial findings.
For issues such losses to follow-up, missing data, and pro-
tocol violations, we will attempt sensitivity analyses to
explore the effect of these factors on the trial findings. As
a secondary analysis, we will adjust for missing data using
imputation techniques to explore the effects of such
imputations on the trial findings.
Interim analysis and data and safety monitoring
The trial will be monitored by a Data Monitoring and Eth-
ics Committee (DMEC). The DMEC has members with
clinical and statistical background, who have no conflict
of interest relating to the three trial protocols and have no
involvement in running of any part of the trial. The DMEC
is responsible for Data and Safety Monitoring. During the
trial the DMEC will perform interim analysis and review
GnRH antagonist regimen Figure 5
GnRH antagonist regimen.Reproductive Health 2007, 4:12 http://www.reproductive-health-journal.com/content/4/1/12
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unblinded outcome data for safety and efficacy. The first
interim analysis is scheduled to take place after primary
outcome data are available for 40% of the trial partici-
pants, and subsequently at four monthly intervals.
Ethics and confidentiality
This trial will be conducted according to the Principles of
Good Clinical Practice as defined in the Medicines for
Human Use (Clinical Trials) Amended Regulations 2006,
the Research Governance Framework for Health & Social
Care 2005 and the Data Protection Act. The trial has
already received a favourable ethical opinion from a
Regional Ethics Committee (REC).
Patient notes containing their personal and treatment
details will be kept within the ACU according to the stat-
utory requirements of the HFE Act 1990 and the strict con-
fidentiality that it requires. Notes from patients who have
achieved a pregnancy will be kept or archived for 50 years.
Patients will need to give their written consent before any
of their treatment details or personal information is
passed to their General Practitioners or any other persons
who are not covered by an HFEA licence.
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